The European Medicines Agency (EMA) announced on Monday 25 October that it had begun the rolling review of a new candidate treatment for Covid-19: molnupiravir (MK-4482 or Lagevrio), an oral antiviral developed by the American pharmaceutical companies Merck Sharp & Dohme and Ridgeback Biotherapeutics.
Preliminary results from laboratory studies indicate that the drug “may reduce the ability of SARS-CoV-2 to multiply in the body, thereby preventing hospitalisation or death in patients with...